Tag: licensing
-
Genome Editing Company Licenses University Technologies
1 December 2014. Editas Medicine, a Cambridge, Massachusetts start-up, licensed technologies developed by the company’s scientific founders and others that allow for editing the human genome to create new therapies. Financial terms of the exclusive licensing deals with Harvard University, MIT, Massachusetts General Hospital, and Duke University were not disclosed. Editas Medicine, founded in 2013,…
-
Type 2 Diabetes Technology Licensed in $1 Billion Deal
12 November 2014. Intarcia Therapeutics Inc., developing a drug and delivery mechanism to treat type 2 diabetes, licensed its technology to the pharmaceutical company Servier in a deal with a potential value of $1 billion. The agreement gives Servier exclusive rights to Intarcia’s diabetes treatment technology to regions outside of the U.S. and Japan. Intarcia’s…
-
Trial Shows Engineered Antibody Relieves Psoriasis
11 November 2014. A late-stage clinical trial shows a monoclonal antibody, a type of engineered biological therapy, cleared more people of the skin condition plaque psoriasis than a placebo or a competitive treatment. The biologic drug, brodalumab, is developed by the biotechnology company Amgen and pharmaceutical maker AstraZeneca. Plaque psoriasis is the most common type…
-
Biosimilars Developer Lands $85 Million in IPO
7 November 2014. Coherus BioSciences Inc., a company developing medications comparable to brand-name biologic therapies, raised $85 million yesterday in its initial public stock offering. The Redwood City, California company trades on the NASDAQ exchange under the symbol CHRS. Coherus valued its 6,296,300 initial shares at $13.50. The stock opened today at $12.74 a share,…
-
Patent Issued for Engineered Peptides Forming Hydrogels
4 November 2014. Bioengineers at Kansas State University received a patent for their invention of a peptide, a protein-like compound, that turns into water-based gels for a number of medical applications. U.S. Patent and Trademark Office awarded patent number 8,835,395 to Xiuzhi (Susan) Sun, professor of grain science and bioengineering at Kansas State, as well…
-
Ebola-Marburg Vaccine Development, Testing Contract Awarded
31 October 2014. A biodefense unit of the U.S. Department of Defense awarded a contract to vaccine maker Profectus BioSciences Inc. for development and testing of a vaccine protecting against the two major Ebola strains and related Marburg viruses. The $9.5 million contract with the Baltimore company came from DoD’s Medical Countermeasure Systems-Joint Vaccine Acquisition…
-
Drug/Device Therapy Trial Shows Fast Migraine Relief
30 October 2014. A late-stage clinical trial shows a medical device designed to deliver migraine drugs deep into nasal cavities achieved headache relief in as little as 30 minutes among patients, and sustained that relief for as long as 48 hours compared to a placebo. The biopharmaceutical company Avanir Pharmaceuticals Inc. in Aliso Viejo, California…
-
Biotech, McGill Univ Partner on Soil Enhancement Microbes
23 October 2014. Inocucor Technologies Inc. and McGill University are collaborating on development of new types of microbes that improve soil for greater yields of large-scale crops such as corn and soybeans. Financial details of the research and licensing agreement between the company and university, both in Montreal, Quebec, Canada, were not disclosed. Inocucor Technologies…
-
Project Developing DNA Antibodies for Infectious Diseases
21 October 2014. The biotechnology company Inovio Pharmaceuticals Inc. and partners are developing synthetic antibodies based on DNA that generate an immune reaction to prevent infectious diseases, a project funded by Department of Defense Advanced Research Projects Agency or DARPA. The $12.2 million DARPA grant is supporting the work of Inovia, in Plymouth Meeting, Pennsylvania,…
-
Personalized Leukemia Immunotherapy Gets 90 Pct Remission
16 October 2014. Nine in 10 children and adults in early-stage clinical trials of a personalized therapy harnessing the patients’ immune systems achieved full remission of their acute lymphoblastic leukemia. The findings of the team from University of Pennsylvania and Children’s Hospital of Philadelphia are reported today in New England Journal of Medicine (paid subscription…